You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 134 No. 4, April 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on ISI (25)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Dermatology, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Topical Cyproterone Acetate Treatment in Women With Acne

A Placebo-Controlled Trial

Doris M. Gruber, MD; Michael O. Sator, MD; Elmar A. Joura, MD; Eva Maria Kokoschka, MD; Georg Heinze, MSc; Johannes C. Huber, MD, PhD

Arch Dermatol. 1998;134:459-463.

Objective  To evaluate the clinical and hormonal response of topically applied cyproterone acetate, oral cyproterone acetate, and placebo lotion in women with acne.

Design  Placebo-controlled, randomized study.

Setting  Patients were recruited from the Institute of Endocrine Cosmetics, Vienna, Austria.

Patients  Forty women with acne.

Interventions  Treatment with oral medication consisting of 0.035 mg of ethinyl estradiol and 2 mg of cyproterone acetate (n=12), 20 mg of topical cyproterone acetate lotion (n=12), and placebo lotion (n=16) was offered. Patients were assessed monthly for 3 months.

Main Outcome Measures  Clinical grading according to acne severity and lesion counts as well as determinations of serum cyproterone acetate concentrations.

Results  After 3 months of therapy with topical cyproterone acetate, the decrease of mean facial acne grade from 1.57 to 0.67 was significantly better (P<.05) compared with placebo (which showed a change from 1.57 to 1.25), but not compared with oral medication (1.56 to 0.75) (P>.05). Lesion counts also decreased from 35.9 to 9.1 in the topical cyproterone acetate group compared with oral medication (45.4 to 15.5) (P>.05) and placebo (38.2 to 23.1) (P<.05). After topical cyproterone acetate treatment, serum cyproterone acetate concentrations were 10 times lower than those found after oral cyproterone acetate intake.

Conclusions  The therapeutic effect of topically applied cyproterone acetate for acne treatment was clearly demonstrated. Topically applied sexual steroids in combination with liposomes are as effective as oral antiandrogen medication in acne treatment, while reducing the risk of adverse effects and avoiding high serum cyproterone acetate concentrations.


From the Division of Gynecological Endocrinology and Reproductive Medicine (Drs Gruber, Sator, and Huber), Department of Gynecology and Obstetrics, Division of Gynecology (Dr Joura), Department of Dermatology (Dr Kokoschka), and Department of Computer Sciences (Mr Heinze), General Hospital, University of Vienna, Vienna, Austria.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Response of Skin Disease to Stress: Changes in the Severity of Acne Vulgaris as Affected by Examination Stress
Chiu et al.
Arch Dermatol 2003;139:897-900.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.